Fecal Microbial Transplantation in Inflammatory Bowel Disease: A Movement Too Big to Be Ignored

Clinical Pharmacology and Therapeutics

Volumn 102, Issue 4, 2017, Pages 588-590

  Laffin, M ^a,b   Madsen, K L ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Centre of Excellence for Gastrointestinal Inflammation and Immunity Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE MEDICINE; ANTIBIOTIC THERAPY; ARTICLE; BLAUTIA; CLOSTRIDIUM; COMMUNITY STRUCTURE; CROHN DISEASE; FECAL MICROBIOTA TRANSPLANTATION; FUSOBACTERIUM; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; LIFESTYLE MODIFICATION; MICROCOSM; NONHUMAN; PARABACTEROIDES; PATIENT SAFETY; PRIORITY JOURNAL; REMISSION; RUMINOCOCCUS; THERAPY EFFECT; ULCERATIVE COLITIS; ADVERSE EFFECTS; INFLAMMATORY BOWEL DISEASES; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

FECAL MICROBIOTA TRANSPLANTATION; HUMANS; INFLAMMATORY BOWEL DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 85022334518     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.747     Document Type: Article

References (5)

1. Van Nood, E. et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 368, 407–415 (2013).
2. Colman, R.J. & Rubin, D.T. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J. Crohns Colitis 8, 1569–1581 (2014).
3. Rossen, N.G. et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149, 110–118.e4 (2015).
4. Moayyedi, P. et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149, 102–109.e6 (2015).
5. Paramsothy, S. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet (2017) doi:10.1016/S0140-6736(17)30182-4 [Epub ahead of print].